Literature DB >> 32464219

OroxylinA reverses lipopolysaccharide-induced adhesion molecule expression and endothelial barrier disruption in the rat aorta.

Tzu-Ling Tseng1, Mei-Fang Chen2, Yung-Hsiang Hsu3, Tony J F Lee4.   

Abstract

Vascular dysfunction plays a critical role in the pathogenesis of sepsis. We elucidated the mechanisms underlying the amelioration of lipopolysaccharide (LPS)-induced vascular inflammation by oroxylin A (OroA) post-treatment in rats. The animals were intraperitoneally injected with LPS (10 mg/kg) to induce systemic inflammation and intravenously (iv) administered OroA (15 mg/kg) 6 h after the LPS treatment. The assessments included biochemical changes in peripheral blood, vascular reactivity which was evaluated by blood-vessel myography, morphological/histological assessment of inflammation, toll-like receptor (TLR)-4-mediated interleukin-1-receptor-associated-kinase (IRAK)-4 activation, changes in adhesion molecule expression, and endothelial junctional stability in the aorta. LPS significantly enhanced the proinflammatory cytokine release, increased vascular cell adhesion molecule (VCAM)-1 expression, disrupted endothelial tight junction, reduced vascular endothelial barrier stability, and increased macrophage infiltration and accumulation in the aorta. All observed pathological changes and vascular inflammation were significantly reversed by the OroA post-treatment. Importantly, OroA suppressed the increased adhesion molecule expression and the endothelial barrier disruption by inhibiting LPS-activated IRAK-4-targeted inhibitory nuclear factor kappa B kinase (IKK) α/β complex phosphorylation, without directly affecting the interaction between LPS and TLR-4. Moreover, the iNOS activity induced by the LPS challenge was inhibited by the OroA pretreatment of the isolated aortic rings. These results suggest that OroA regulates the vascular tone by inhibiting vascular hyporeactivity caused by NO overproduction and reverses the endothelial barrier dysfunction and inflammation by inhibiting the IRAK-4-mediated IKKα/β phosphorylation. Overall, these findings suggest OroA administration as a potentially useful therapeutic approach for clinical interventions in septic shock.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adhesion molecule; Endothelial barrier disruption; LPS; OroxylinA (OroA); Vascular inflammation

Year:  2020        PMID: 32464219     DOI: 10.1016/j.taap.2020.115070

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  3 in total

1.  Therapeutic mechanism of Toujie Quwen granules in COVID-19 based on network pharmacology.

Authors:  Ying Huang; Wen-Jiang Zheng; Yong-Shi Ni; Mian-Sha Li; Jian-Kun Chen; Xiao-Hong Liu; Xing-Hua Tan; Ji-Qiang Li
Journal:  BioData Min       Date:  2020-09-24       Impact factor: 2.522

2.  A Candidate Drug Screen Strategy: The Discovery of Oroxylin A in Scutellariae Radix Against Sepsis via the Correlation Analysis Between Plant Metabolomics and Pharmacodynamics.

Authors:  Lingyu Han; Yue Yuan; Xinyi Chen; Jian Huang; Guan Wang; Chao Zhou; Jianjian Dong; Na Zhang; Yuxin Zhang; Hang Yin; Yunyao Jiang
Journal:  Front Pharmacol       Date:  2022-05-19       Impact factor: 5.988

3.  A systematic review and meta-analyses of interleukin-1 receptor associated kinase 3 (IRAK3) action on inflammation in in vivo models for the study of sepsis.

Authors:  Trang H Nguyen; Ilona Turek; Terri Meehan-Andrews; Anita Zacharias; Helen R Irving
Journal:  PLoS One       Date:  2022-02-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.